Noubar Afeyan Net Worth

The estimated Net Worth of Noubar Afeyan is at least $1.82 Miliarda dollars as of 31 July 2024. Noubar Afeyan owns over 15,000 units of Moderna Inc stock worth over $176,831,433 and over the last 20 years he sold MRNA stock worth over $1,647,091,781. In addition, he makes $530,000 as Non-Executive Independent Chairman of the Board a Co-Founder at Moderna Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Noubar Afeyan MRNA stock SEC Form 4 insiders trading

Noubar has made over 87 trades of the Moderna Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of MRNA stock worth $1,799,400 on 31 July 2024.

The largest trade he's ever made was buying 8,888,888 units of Moderna Inc stock on 18 June 2019 worth over $19,999,998. On average, Noubar trades about 178,391 units every 16 days since 2004. As of 31 July 2024 he still owns at least 2,224,015 units of Moderna Inc stock.

You can see the complete history of Noubar Afeyan stock trades at the bottom of the page.

Noubar Afeyan biography

Dr. Noubar B. Afeyan Ph.D. serves as Non-Executive Independent Chairman of the Board, Co-Founder of the Company. Dr. Afeyan is a co-founder and has served on our board of directors since incorporation, and has served as a chairman of our board of directors since February 2012. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since April 2013, Dr. Afeyan has served on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY) and since October 2010, on the board of Seres Therapeutics, Inc. (Nasdaq: MCRB). He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Evelo Biosciences, Inc. (Nasdaq: EVLO), Kaleido Biosciences, Inc. (Nasdaq: KLDO) and BG Medicine, Inc (OTCMKTS: BGMD). He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (“MIT”) and a B.S. in chemical engineering from McGill University. Dr. Afeyan is currently a visiting lecturer of business administration at Harvard Business School and was previously a senior lecturer at MIT’s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. Afeyan’s significant experience co-founding, leading, and investing in numerous biotechnology companies make him qualified to serve on our board of directors.

What is the salary of Noubar Afeyan?

As the Non-Executive Independent Chairman of the Board a Co-Founder of Moderna Inc, the total compensation of Noubar Afeyan at Moderna Inc is $530,000. There are 11 executives at Moderna Inc getting paid more, with Stephane Bancel having the highest compensation of $8,948,210.

What's Noubar Afeyan's mailing address?

Noubar's mailing address filed with the SEC is 325 Vassar St Suite 1A, Cambridge, MA 02139, USA.

Insiders trading at Moderna Inc

Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein a Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.

What does Moderna Inc do?

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a

Complete history of Noubar Afeyan stock trades at Agenus Inc, Seres Therapeutics Inc, Evelo Biosciences Inc, Rubius Therapeutics Inc a Moderna Inc

Moderna Inc executives and stock owners

Moderna Inc executives and other stock owners filed with the SEC include:

• Stephane Bancel,
  Chief Executive Officer, Director
• Stephen Hoge,
  President
• Tal Zvi Zaks,
  Chief Medical Officer
• Juan Andres,
  Chief Technical Operations and Quality Officer
• Stephane Bancel,
  CEO & Director
• Stéphane Bancel,
  CEO & Director
• Dr. Stephen Hoge M.D.,
  Pres
• Dr. Stephen Hoge,
  Pres
• Juan Andres,
  Chief Technical Operations & Quality Officer
• David W. Meline,
  CFO & Principal Accounting Officer
• Francois Nader,
  Non-Executive Independent Director
• Noubar Afeyan,
  Non-Executive Independent Chairman of the Board, Co-Founder
• Israel Ruiz,
  Non-Executive Independent Director
• Robert Langer,
  Non-Executive Independent Director
• Stephen Berenson,
  Non-Executive Independent Director
• Paul Sagan,
  Non-Executive Independent Director
• Dr. Noubar B. Afeyan Ph.D.,
  Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board
• Elizabeth Tallett,
  Director
• Ray Jordan,
  Chief Corporate Affairs Officer
• Marcello Damiani,
  Chief Digital and Operational Excellence Officer
• Lori Henderson,
  General Counsel, Company Secretary
• Tracey Franklin,
  Chief Human Resource Officer
• David Meline,
  Chief Financial Officer
• Colleen Hussey,
  Sr. Mang. of Corp. Communications
• Shannon Thyme Klinger,
  Chief Legal Officer & Corp. Sec.
• Lori M. Henderson J.D., Esq.,
  Gen. Counsel & Corp. Sec.
• Lavina Talukdar CFA,
  Sr. VP & Head of Investor Relations
• Dr. Melissa J. Moore,
  Chief Scientific Officer & Member of Scientific Advisory Board
• Dr. John V. W. Reynders,
  Chief Information Officer
• Lorence H. Kim,
  Chief Financial Officer
• Elizabeth G Nabel,
  Director
• Noubar Flagship Ventures Fu...,
  
• Shannon Thyme Klinger,
  Chief Legal Officer
• Jennifer Ling Lee,
  Chief Accounting Officer
• Sandra Horning,
  Director
• Peter Barton Hutt,
  Director
• Moncef Slaoui,
  Director
• Ventures Fund Iv General Pa...,
  
• Edwin M Jr Kania,
  10% owner
• Ventures Fund Iv General Pa...,
  
• Goff Corinne Le,
  Chief Commercial Officer
• Paul Burton,
  Chief Medical Officer
• James M Mock,
  Chief Financial Officer
• Arpa Garay,
  Chief Commercial Officer
• David M. Rubenstein,
  Director